微信直播

首届中国肺癌精准诊疗论坛|Prof. Feng-Ming Kong:刀剑无眼,放射肿瘤学工作者需要博学而审慎

Published at: 2015年第1卷第S1期

何朝秀
关键词:

编者按:今年5月于北京举行的首届中国肺癌精准论坛暨第四届国家癌症中心年会上,我们采访到了美国放射学院院士,放射肿瘤学专家Feng-Ming(Spring) Kong(孔凤鸣)教授。孔教授是中美放射肿瘤协会首任会长,第一任董事长, 现美国印第安纳州大学医学院放射肿瘤学的终身教授,临床放疗研究主任, 胸部肿瘤学合同领头人。

访谈初始,孔教授便从自身经历娓娓道来,不仅分享了自身的研究领域,同时也讲述了当初为何选择了放射肿瘤学这一领域,成我国第一个放射肿瘤学博士,转而到了美国Duke University, Washington University at St. Louis, University of Michigan, Georgia Augusta University, Indiana University 等知名学府和医学中心深造,行医并担任主要领导责位。纵其在中美的所见所闻,孔教授分别从住院医师培训、设备与技术、专业人员的分工与团队配置等方面来阐述了中美在放射肿瘤学科领域的异同,希望这将有利于促进中美之间的交流与进步,创造更多的合作机会。

访谈中最让小编印象深刻的一句话是,“Radiation can kill cancers without bleeding, can also hurt even kill patients without seeing blood, without people knowing it...technology and knowledge guided precision medicine is A MUST! The challenges of radiation therapy is that the treatment outcome, good or bad, sometimes is often not apparent to us...you have to be knowledgeable and mindful careful when you give this kind of care or treatment.”正如刀剑无眼,放射肿瘤学科的技术就如同一把双刃剑,用者需博学而审慎,用之准确,则造福病人;用之不当则可能遗害无穷。所以追求精准,再精准,也一直是放射肿瘤学科至始至终在追求的。致此,与大家共勉!

 

访谈视频


 

访谈问题

  1. Would you like to share your research focus? How did you start your career on the research?

  2. As you have the study and working experience in both China and US, do you find any differences in the field of radiation oncology between the two countries?

  3. Do you think the number of patients who receive radiotherapy is much fewer in China?

  4. How do you look at the rapid change of technology in the field of radiation oncology?

     

专家简介

 

Feng-Ming (Spring) Kong, MD, PhD, Thoracic Radiation Oncologist, Fellow of American College of Radiology, The First President and Chair of Sino-American Network for Therapeutic Radiology and Oncology. Currently she is a tenured Professor in Indiana University, department of radiation oncology, Melvin and Bren Simon Cancer Center, Indianapolis, IN., USA

Prof. Kong’s academic interests include image-guided and molecular marker-guided individualized adaptive radiation therapy, gene therapy for radiation-induced lung toxicity, predictive biomarkers for survival and treatment side effects of radiation therapy, and modern stereotactic radiation technology to modulate immunofunction. Prof. Kong is the principal investigator of a multicenter clinical trial cosponsored by the Radiation Therapy Oncology Group and the American College of Radiology Imaging Network using PET and modern technology to individualize radiation therapy in non-small cell lung cancer (RTOG1106). Prof. Kong is funded both internationally and nationally by the National Institutes of Health for clinical trials related to non-small cell lung cancer. In addition to general radiation oncology and stereotactic body radiation therapy, Prof. Kong’s clinical interests include radiation therapy and multidisciplinary care for lung cancer, esophageal cancer, thymoma, mesothelioma, liver cancer as well as any metastatic cancers. Prof. Kong's ambitious goal is to, by the use of modern technology, maximize tumor control and minimize treatment toxicities of critical structures including lung, heart, esophagus, and immune system. 

 

采访编辑:何朝秀, AME出版社科学编辑

视频编辑:施云彪,AME出版社视频编辑

 

相关阅读:

doi: 10.3978/kysj.2014.1.1954

comments powered by Disqus

附件